Partitioning of TSE infectivity during ethanol fractionation of human plasma

Biologicals

Volumn 32, Issue 1, 2004, Pages 1-10

  Gregori, L ^b   Maring, J A ^a   MacAuley, C ^b   Dunston, B ^b   Rentsch, M ^a   Kempf, C ^a,c   Rohwer, R G ^b  

^a ZLB Bioplasma AG   (Switzerland)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALCOHOL; IMMUNOGLOBULIN; PROTEINASE K;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CONTROLLED STUDY; DISEASE TRANSMISSION; FRACTIONATION; HAMSTER; INFECTION; NANOFILTRATION; NONHUMAN; PLASMA; PRION DISEASE; PRIORITY JOURNAL; SCRAPIE AGENT; SHEEP; WESTERN BLOTTING;

ANIMALS; BLOOD; BLOTTING, WESTERN; BRAIN; CRICETINAE; ENDOPEPTIDASE K; ETHANOL; HUMANS; IMMUNOGLOBULINS; PRION DISEASES; SERUM ALBUMIN; SHEEP; SUBCELLULAR FRACTIONS; TIME FACTORS;

CRICETINAE; OVIS ARIES;

EID: 1542617768     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biologicals.2003.08.004     Document Type: Article

References (38)

1. Busch M.P. HIV, HBV and HCV: New developments related to transfusion safety. Vox Sang. 78:(suppl 2):2000;253-256.
2. Hoots W.K. History of plasma-product safety. Transfus Med Rev. 15:(suppl 1):2001;3-10.
3. Prusiner S.B. Novel proteinaceous infectious particles. Science. 216:1982;136-144.
4. Rohwer R.G. The scrapie agent: "A virus by any other name" Curr Top Microbiol Immunol. 172:1991;195-232.
5. Somerville R.A. TSE agent strains and PrP: reconciling structure and function. Trends Biochem Sci. 27:2002;606-612.
6. Nandi P.K., Leclerc E., Nicole J.C., Takahashi M. DNA-indiced partial unfolding of prion protein leads to its polymerization to amyloid. J Mol Biol. 322:2002;153-161.
7. Bruce M.E., Will R.G., Ironside J.W., McConnell I., Drummond D., Suttie A., et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature. 389:1997;498-501.
8. Hill A.F., Desbruslais M., Joiner S., Sidle K.C., Gowland I., Collinge J., et al. The same prion strain causes vCJD and BSE. Nature. 389:1997;448-550.
9. Brown P., Rohwer R.G., Dunston B.C., MacAuley C., Gajdusek D.C., Drohan W.N. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion. 38:1998;810-816.
10. Brown P., Cervenakova L., McShane L.M., Barber P., Rubenstein R., Drohan W.N. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion. 39:1999;1169-1178.
11. Houston F., Foster J.D., Chong A., Hunter N., Bostock C.J. Transmission of BSE by blood transfusion in sheep. Lancet. 356:2000;999-1000.
12. Hunter N., Foster J., Chong A., McCutcheon S., Parnham D., Eaton S., et al. Transmission of prion diseases by blood transfusion. J Gen Virol. 83:2002;2897-2905.
13. Bons N., Lehmann S., Mestre-Frances N., Dormont D., Brown P. Brain and buffy coat transmission of bovine spongiform encephalopathy to the primate Microcebus murinus. Transfusion. 42:2002;513-516.
14. van Dujin C.M., Delasnierie-Lauprêtre N., Masullo C., Zerr I., de Silva R., Wientjens D.P.W.M., et al. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95. Lancet. 351:1998;1081-1085.
15. Evatt B., Austin H., Barnhart E., Schonberger L., Sharer L., Jones R., et al. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia. Transfusion. 38:1998;817-820.
16. Lee C.A., Ironside J.W., Bell J.E., Giangrande P., Ludlam C., Esiri M.M., et al. Retrospective neuropathological review of prion disease in UK haemophilic patients. Thromb Haemost. 80:1998;909-1111.
17. Brown P. Variant CJD transmission through blood: risks to predictors and "predictees" Transfusion. 43:2003;425-427.
18. Hill A.F., Zeidler M., Ironside J., Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet. 349:1997;99-100.
19. Hilton D.A., Fathers E., Edwards P., Ironside J.W., Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet. 29:1998;703-704.
20. Brown P. Donor pool size and the risk of blood-borne Creutzfeld-Jakob disease. Transfusion. 38:1998;312-315.
21. Rohwer R.G. Analysis of risk to biomedical products developed from animal sources (with special emphasis on the spongiform encephalopathy agents, scrapie and BSE). Dev Biol Stand. 88:1996;247-256.
22. Taylor D.M. Inactivation of transmissible degenerative encephalopathy agents: A review. Vet J. 159:2000;10-17.
23. Tateishi J., Kitamoto T., Mohri S., Satoh S., Sato T., Shepherd A., et al. Scrapie removal using Planova virus removal filters. Biologicals. 29:2001;17-25.
24. Van Holten R.W., Autenrieth S., Boose J.A., Hsieh W.T., Dolan S. Removal of prion challenge from an immune globulin preparation by use of a size-exclusion filter. Transfusion. 42:2002;999-1004.
25. Kempf C., Morgenthaler J.J., Rentsch M., Omar A. Viral safety and manufacturing of an intravenous immunoglobulin. Kazatchkine, Morell. Intravenous Immunoglobulin Research and Therapy. 1996;11-18 Parthenon Publishing Group.
26. Omar A., Morgenthaler J.J. Method for the removal of viruses from protein solutions. USP. 5:1997;236-696.
27. Morgenthaler J.J., Maring J.-A., Rentsch M. Method for the removal of causative agents(s) of transmissible spongiform encephalopathies from protein solutions. USP. 6:2002;212-407.
28. Kistler P., Nitschmann H. Large-scale production of human plasma fractions. Vox Sang. 7:1962;414-424.
29. Reed L.J., Muench H.A. Simple method of determining fifty percent enpoints. Am J Hyg. 27:1938;494-497.
30. Kascsak R.J., Rubenstein R., Merz P.A., Tonna-DeMasi M., Fersko R., Carp R.I., et al. Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol. 61:1987;3688-3693.
31. Beekes M., Baldauf E., Cassens S., Diringer H., Keyes P., Scott A.C., et al. Western blot mapping of disease-specific amyloid in various animal species and humans with transmissible spongiform encephalopathies using a high-yield purification method. J Gen Virol. 76:1995;2567-2576.
32. Vey M., Baron H., Weimer T., Groner A. Purity of spiking agent affects partitioning of prions in plasma protein purification. Biologicals. 30:2002;187-196.
33. Reichl H.E., Foster P.R., Welch A.G., Li Q., MacGregor I.R., Somerville R.A., et al. Studies on the removal of a bovine spongiform encephalopathy- derived agent by processes used in the manufacture of human immunoglobulin. Vox Sang. 83:2002;137-145.
34. Lee D.C., Stenland C.J., Miller J.L., Cai K., Ford E.K., Gilligan K.J., et al. A direct relationship between the partion of the pathogenic prion protein and the transmissible spongiform encephalopathy infectivity during the purification of plasma products. Transfusion. 41:2001;449-455.
35. Foster P.R. Prions and blood products. Ann Med. 32:2000;501-513.
36. Foster P.R., Welch A.G., McLean C., Griffin B.D., Hardy J.C., Bartley A., et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang. 78:2000;86-95.
37. Lee D.C., Stenland C.J., Hartwell R.C., Ford E.K., Cai K., Miller J.L., et al. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods. 84:2000;77-89.
38. Stenland C.J., Lee D.C., Brown P., Petteway S.R. Jr, Rubenstein R. Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. Transfusion. 42:2002;1497-1500.